Embecta announced it has completed its previously announced acquisition of Owen Mumford Holdings Limited, a privately held innovator and manufacturer of medical devices and drug delivery technologies.
The companies had previously announced a definitive agreement on March 19, 2026, under which embecta agreed to acquire Owen Mumford for an upfront cash payment of £100 million and up to an additional £50 million in performance-based payments tied to net sales of the Aidaptus® next-generation auto-injector platform during the three years following closing.
Embecta said the acquisition accelerates its strategic transformation into a broader medical supplies company serving chronic care patients across obesity, diabetes, autoimmune diseases, and anaphylaxis markets. The company added that the transaction provides a differentiated drug-delivery platform, expands its intellectual property portfolio, and enhances its ability to support pharmaceutical partners across multiple therapeutic areas.
The deal also combines Owen Mumford’s device design, molding, and assembly capabilities with embecta’s global commercial infrastructure and large-scale manufacturing expertise, which the companies believe will create opportunities for geographic expansion and operational efficiencies.
Founded in 1952 and headquartered in Oxfordshire, United Kingdom, Owen Mumford has developed healthcare devices and drug delivery technologies for more than 70 years. The company’s portfolio includes self-injection, diagnostics, and patient-focused healthcare solutions distributed globally.
